Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.51 |
| ▸ | NQO1 | P15559 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358751 | 1.00 | CES1 (0.51) | CES1NQO1CYP1A2ACHEERBB2 | |
| SCHEMBL6250997 | 0.78 | CES1 (0.51) | CES1NQO1CYP1A2ALDH1A1HPGD | |
| SCHEMBL6250540 | 0.78 | NQO1 (0.49) | CES1NQO1CYP1A2ALDH1A1HPGD | |
| SCHEMBL4977411 | 0.77 | CES1 (0.43) | CES1NQO1CYP1A2ACHEERBB2 | |
| SCHEMBL29562021 | 0.74 | CYP1A2 (0.47) | CES1NQO1CYP1A2ACHEERBB2 | |
| SCHEMBL26028 | 0.74 | CYP1A2 (0.47) | CES1NQO1CYP1A2ACHEERBB2 | |
| SCHEMBL21832124 | 0.74 | CES1 (0.49) | CES1NQO1CYP1A2ACHEERBB2 | |
| Triphenylene SCHEMBL22493025 | 0.73 | CYP1A2 (0.46) | CES1NQO1CYP1A2ACHEERBB2 | |
| SCHEMBL7741289 | 0.72 | CES1 (0.38) | CES1CYP1A2ACHEALDH1A1HPGD | |
| SCHEMBL5716919 | 0.72 | CES1 (0.79) | CES1NQO1CYP1A2ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695308-A1 | ENGINEERED ANTIBODIES AND USES THEREOF | Invitrogen BioServices India Private Limited (IN) | 2026-02-18 | — | — | EP | claimed |
| WO-2025057225-A1 | ENGINEERED ANTIBODIES AND USES THEREOF | INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED (IN) | 2025-03-20 | — | — | WO | claimed |
| EP-4695308-A1 | ENGINEERED ANTIBODIES AND USES THEREOF | Invitrogen BioServices India Private Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025057225-A1 | ENGINEERED ANTIBODIES AND USES THEREOF | INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED (IN) | 2025-03-20 | — | — | WO | disclosed |
| US-20240327655-A1 | DYE-LABELED POLYMERS AND METHODS FOR PREPARING SAME | DEBOGY MOLECULAR, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-116173036-A | E Mi Litong for glioma | 昂克希尔迪克斯有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115803333-A | Trinucleotide cap analogs, their preparation and use | 生命技术公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022204569-A1 | DYE-LABELED POLYMERS AND METHODS FOR PREPARING SAME | DEBOGY MOLECULAR, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-110546273-A | quantification of NGS DNA by adaptor sequences | LIFE TECHNOLOGIES CORP | 2019-12-06 | — | — | CN | disclosed |
| US-20050250957-A1 | Compounds containing thiosulfate moieties | MOLECULAR PROBES, INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005047242-A2 | COMPOUNDS CONTAINING THIOSULFATE MOIETIES | MOLECULAR PROBES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-5362628-A | Analyzing | MOLECULAR PROBES, INC. (US) | 1994-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327655-A1 | DYE-LABELED POLYMERS AND METHODS FOR PREPARING SAME | ALG1, CD99, GUSB | CES1 2129/4885NQO1 4837/4885CYP1A2 3072/4885 |
| US-20050250957-A1 | Compounds containing thiosulfate moieties | TST, MPST, STS | CES1 2063/4885NQO1 113/4885CYP1A2 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.